Survival Benefit of Crossover Administration of Regorafenib and Trifluridine/Tipiracil Hydrochloride for Patients With Metastatic Colorectal Cancer: Exploratory Analysis of a Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study (REGOTAS)
Background: The survival benefits of regorafenib (REG) and trifluridine/tipiracil hydrochloride (TFTD) have been demonstrated in chemorefractory patients with metastatic colorectal cancer (mCRC). However, the effects of crossover administration of REG and TFTD on patient survival remain unclear. The...
| Main Authors: | , , , , , , , , , , , , , , , , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2021-03-01
|
| Series: | Frontiers in Oncology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fonc.2021.576036/full |
| _version_ | 1818558755374104576 |
|---|---|
| author | Keigo Chida Daisuke Kotani Toshikazu Moriwaki Shota Fukuoka Toshiki Masuishi Atsuo Takashima Yosuke Kumekawa Takeshi Kajiwara Kentaro Yamazaki Masato Komoda Akitaka Makiyama Akitaka Makiyama Tadamichi Denda Yukimasa Hatachi Takeshi Suto Naotoshi Sugimoto Masanobu Enomoto Toshiaki Ishikawa Tomomi Kashiwada Koji Ando Satoshi Yuki Yoshihiro Okita Hitoshi Kusaba Daisuke Sakai Koichi Okamoto Takao Tamura Kimihiro Yamashita Masahiko Gosho Yasuhiro Shimada |
| author_facet | Keigo Chida Daisuke Kotani Toshikazu Moriwaki Shota Fukuoka Toshiki Masuishi Atsuo Takashima Yosuke Kumekawa Takeshi Kajiwara Kentaro Yamazaki Masato Komoda Akitaka Makiyama Akitaka Makiyama Tadamichi Denda Yukimasa Hatachi Takeshi Suto Naotoshi Sugimoto Masanobu Enomoto Toshiaki Ishikawa Tomomi Kashiwada Koji Ando Satoshi Yuki Yoshihiro Okita Hitoshi Kusaba Daisuke Sakai Koichi Okamoto Takao Tamura Kimihiro Yamashita Masahiko Gosho Yasuhiro Shimada |
| author_sort | Keigo Chida |
| collection | DOAJ |
| description | Background: The survival benefits of regorafenib (REG) and trifluridine/tipiracil hydrochloride (TFTD) have been demonstrated in chemorefractory patients with metastatic colorectal cancer (mCRC). However, the effects of crossover administration of REG and TFTD on patient survival remain unclear. The present study evaluated the association between exposure to REG and TFTD and overall survival (OS) in patients with mCRC using data from the REGOTAS study.Patients and Methods: We analyzed patients registered in the REGOTAS study, which retrospectively compared the efficacy and safety of use of REG or TFTD as later-line chemotherapy for chemorefractory mCRC patients. We compared the survival outcomes of cohort A (treated using both REG and TFTD) and cohort B (treated using either REG or TFTD).Results: A total of 550 patients (cohort A, n = 252; cohort B, n = 298) met the inclusion criteria. The median OS was significantly increased in cohort A compared with cohort B [9.6 months (95% confidence interval (CI), 8.9–10.9 months) vs. 5.2 months (95% CI, 4.4–6.0 months), P < 0.001]. Multivariate analysis revealed that cohort A was independently associated with a significant increase in OS [A vs. B: Hazard ratios (HR), 0.58; 95% CI, 0.47–0.72; P < 0.001]. Subgroup analysis adjusted using multivariate Cox model revealed a consistently better trend in most subgroups for cohort A compared with cohort B.Conclusions: Our study revealed prolonged survival in patients treated with REG and TFTD. Therefore, all active agents, including REG and TFTD, should be made available to mCRC patients. |
| first_indexed | 2024-12-14T00:16:24Z |
| format | Article |
| id | doaj.art-62fbb44c692c4df88be7192d21a1ba7b |
| institution | Directory Open Access Journal |
| issn | 2234-943X |
| language | English |
| last_indexed | 2024-12-14T00:16:24Z |
| publishDate | 2021-03-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Oncology |
| spelling | doaj.art-62fbb44c692c4df88be7192d21a1ba7b2022-12-21T23:25:31ZengFrontiers Media S.A.Frontiers in Oncology2234-943X2021-03-011110.3389/fonc.2021.576036576036Survival Benefit of Crossover Administration of Regorafenib and Trifluridine/Tipiracil Hydrochloride for Patients With Metastatic Colorectal Cancer: Exploratory Analysis of a Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study (REGOTAS)Keigo Chida0Daisuke Kotani1Toshikazu Moriwaki2Shota Fukuoka3Toshiki Masuishi4Atsuo Takashima5Yosuke Kumekawa6Takeshi Kajiwara7Kentaro Yamazaki8Masato Komoda9Akitaka Makiyama10Akitaka Makiyama11Tadamichi Denda12Yukimasa Hatachi13Takeshi Suto14Naotoshi Sugimoto15Masanobu Enomoto16Toshiaki Ishikawa17Tomomi Kashiwada18Koji Ando19Satoshi Yuki20Yoshihiro Okita21Hitoshi Kusaba22Daisuke Sakai23Koichi Okamoto24Takao Tamura25Kimihiro Yamashita26Masahiko Gosho27Yasuhiro Shimada28Department of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, JapanDepartment of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, JapanDivision of Gastroenterology, Faculty of Medicine, University of Tsukuba, Tsukuba, JapanDepartment of Gastrointestinal Oncology, National Cancer Center Hospital East, Kashiwa, JapanDepartment of Clinical Oncology, Aichi Cancer Center Hospital, Aichi, JapanGastrointestinal Medical Oncology Division, National Cancer Center Hospital, Tokyo, JapanDepartment of Gastroenterology, Saitama Cancer Center, Saitama, JapanDepartment of Gastrointestinal Medical Oncology, National Hospital Organization Shikoku Cancer Center, Ehime, JapanDivision of Gastrointestinal Oncology, Shizuoka Cancer Center, Shizuoka, JapanDepartment of Gastrointestinal and Medical Oncology, National Hospital Organization Kyushu Cancer Center, Fukuoka, JapanDepartment of Hematology/Oncology, Japan Community Healthcare Organization Kyushu Hospital, Fukuoka, Japan0Cancer Center, Gifu University Hospital, Gifu, Japan1Division of Gastroenterology, Chiba Cancer Center, Chiba, Japan2Department of Medical Oncology, Kobe City Medical Center General Hospital, Hyogo, Japan3Department of Gastroenterological Surgery, Yamagata Prefectural Central Hospital, Yamagata, Japan4Department of Medical Oncology, Osaka International Cancer Institute, Osaka, Japan5Department of Gastrointestinal and Pediatric Surgery, Tokyo Medical University, Tokyo, Japan6Department of Specialized Surgeries, Graduate School of Medicine and Dentistry, Tokyo Medical and Dental University, Tokyo, Japan7Division of Hematology, Respiratory Medicine and Oncology, Department of Internal Medicine, Faculty of Medicine, Saga University, Saga, Japan8Department Surgery and Science, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan9Department of Cancer Chemotherapy, Hokkaido University Hospital Cancer Center, Sapporo, Japan0Department of Clinical Oncology, Faculty of Medicine, Kagawa University, Kagawa, Japan1Department of Medicine and Comprehensive Biosystemic Science, Kyushu University Graduate of Medical Sciences, Fukuoka, Japan2Department of Frontier Science for Cancer and Chemotherapy, Osaka University Graduate School of Medicine, Osaka, Japan3Department of Surgery, National Defense Medical College, Tokorozawa, Japan4Department of Medical Oncology, Faculty of Medicine, Kindai University, Osaka, Japan5Division of Gastrointestinal Surgery, Department of Surgery, Graduate School of Medicine, Kobe University, Hyogo, Japan6Department of Biostatistics, Faculty of Medicine, University of Tsukuba, Tsukuba, Japan7Clinical Oncology Division, Kochi Health Sciences Center, Kochi, JapanBackground: The survival benefits of regorafenib (REG) and trifluridine/tipiracil hydrochloride (TFTD) have been demonstrated in chemorefractory patients with metastatic colorectal cancer (mCRC). However, the effects of crossover administration of REG and TFTD on patient survival remain unclear. The present study evaluated the association between exposure to REG and TFTD and overall survival (OS) in patients with mCRC using data from the REGOTAS study.Patients and Methods: We analyzed patients registered in the REGOTAS study, which retrospectively compared the efficacy and safety of use of REG or TFTD as later-line chemotherapy for chemorefractory mCRC patients. We compared the survival outcomes of cohort A (treated using both REG and TFTD) and cohort B (treated using either REG or TFTD).Results: A total of 550 patients (cohort A, n = 252; cohort B, n = 298) met the inclusion criteria. The median OS was significantly increased in cohort A compared with cohort B [9.6 months (95% confidence interval (CI), 8.9–10.9 months) vs. 5.2 months (95% CI, 4.4–6.0 months), P < 0.001]. Multivariate analysis revealed that cohort A was independently associated with a significant increase in OS [A vs. B: Hazard ratios (HR), 0.58; 95% CI, 0.47–0.72; P < 0.001]. Subgroup analysis adjusted using multivariate Cox model revealed a consistently better trend in most subgroups for cohort A compared with cohort B.Conclusions: Our study revealed prolonged survival in patients treated with REG and TFTD. Therefore, all active agents, including REG and TFTD, should be made available to mCRC patients.https://www.frontiersin.org/articles/10.3389/fonc.2021.576036/fullregorafenibtrifluridine/tipiracil hydrochloridecolorectal cancerprognosischemotherapy – oncology |
| spellingShingle | Keigo Chida Daisuke Kotani Toshikazu Moriwaki Shota Fukuoka Toshiki Masuishi Atsuo Takashima Yosuke Kumekawa Takeshi Kajiwara Kentaro Yamazaki Masato Komoda Akitaka Makiyama Akitaka Makiyama Tadamichi Denda Yukimasa Hatachi Takeshi Suto Naotoshi Sugimoto Masanobu Enomoto Toshiaki Ishikawa Tomomi Kashiwada Koji Ando Satoshi Yuki Yoshihiro Okita Hitoshi Kusaba Daisuke Sakai Koichi Okamoto Takao Tamura Kimihiro Yamashita Masahiko Gosho Yasuhiro Shimada Survival Benefit of Crossover Administration of Regorafenib and Trifluridine/Tipiracil Hydrochloride for Patients With Metastatic Colorectal Cancer: Exploratory Analysis of a Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study (REGOTAS) Frontiers in Oncology regorafenib trifluridine/tipiracil hydrochloride colorectal cancer prognosis chemotherapy – oncology |
| title | Survival Benefit of Crossover Administration of Regorafenib and Trifluridine/Tipiracil Hydrochloride for Patients With Metastatic Colorectal Cancer: Exploratory Analysis of a Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study (REGOTAS) |
| title_full | Survival Benefit of Crossover Administration of Regorafenib and Trifluridine/Tipiracil Hydrochloride for Patients With Metastatic Colorectal Cancer: Exploratory Analysis of a Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study (REGOTAS) |
| title_fullStr | Survival Benefit of Crossover Administration of Regorafenib and Trifluridine/Tipiracil Hydrochloride for Patients With Metastatic Colorectal Cancer: Exploratory Analysis of a Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study (REGOTAS) |
| title_full_unstemmed | Survival Benefit of Crossover Administration of Regorafenib and Trifluridine/Tipiracil Hydrochloride for Patients With Metastatic Colorectal Cancer: Exploratory Analysis of a Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study (REGOTAS) |
| title_short | Survival Benefit of Crossover Administration of Regorafenib and Trifluridine/Tipiracil Hydrochloride for Patients With Metastatic Colorectal Cancer: Exploratory Analysis of a Japanese Society for Cancer of the Colon and Rectum Multicenter Observational Study (REGOTAS) |
| title_sort | survival benefit of crossover administration of regorafenib and trifluridine tipiracil hydrochloride for patients with metastatic colorectal cancer exploratory analysis of a japanese society for cancer of the colon and rectum multicenter observational study regotas |
| topic | regorafenib trifluridine/tipiracil hydrochloride colorectal cancer prognosis chemotherapy – oncology |
| url | https://www.frontiersin.org/articles/10.3389/fonc.2021.576036/full |
| work_keys_str_mv | AT keigochida survivalbenefitofcrossoveradministrationofregorafenibandtrifluridinetipiracilhydrochlorideforpatientswithmetastaticcolorectalcancerexploratoryanalysisofajapanesesocietyforcancerofthecolonandrectummulticenterobservationalstudyregotas AT daisukekotani survivalbenefitofcrossoveradministrationofregorafenibandtrifluridinetipiracilhydrochlorideforpatientswithmetastaticcolorectalcancerexploratoryanalysisofajapanesesocietyforcancerofthecolonandrectummulticenterobservationalstudyregotas AT toshikazumoriwaki survivalbenefitofcrossoveradministrationofregorafenibandtrifluridinetipiracilhydrochlorideforpatientswithmetastaticcolorectalcancerexploratoryanalysisofajapanesesocietyforcancerofthecolonandrectummulticenterobservationalstudyregotas AT shotafukuoka survivalbenefitofcrossoveradministrationofregorafenibandtrifluridinetipiracilhydrochlorideforpatientswithmetastaticcolorectalcancerexploratoryanalysisofajapanesesocietyforcancerofthecolonandrectummulticenterobservationalstudyregotas AT toshikimasuishi survivalbenefitofcrossoveradministrationofregorafenibandtrifluridinetipiracilhydrochlorideforpatientswithmetastaticcolorectalcancerexploratoryanalysisofajapanesesocietyforcancerofthecolonandrectummulticenterobservationalstudyregotas AT atsuotakashima survivalbenefitofcrossoveradministrationofregorafenibandtrifluridinetipiracilhydrochlorideforpatientswithmetastaticcolorectalcancerexploratoryanalysisofajapanesesocietyforcancerofthecolonandrectummulticenterobservationalstudyregotas AT yosukekumekawa survivalbenefitofcrossoveradministrationofregorafenibandtrifluridinetipiracilhydrochlorideforpatientswithmetastaticcolorectalcancerexploratoryanalysisofajapanesesocietyforcancerofthecolonandrectummulticenterobservationalstudyregotas AT takeshikajiwara survivalbenefitofcrossoveradministrationofregorafenibandtrifluridinetipiracilhydrochlorideforpatientswithmetastaticcolorectalcancerexploratoryanalysisofajapanesesocietyforcancerofthecolonandrectummulticenterobservationalstudyregotas AT kentaroyamazaki survivalbenefitofcrossoveradministrationofregorafenibandtrifluridinetipiracilhydrochlorideforpatientswithmetastaticcolorectalcancerexploratoryanalysisofajapanesesocietyforcancerofthecolonandrectummulticenterobservationalstudyregotas AT masatokomoda survivalbenefitofcrossoveradministrationofregorafenibandtrifluridinetipiracilhydrochlorideforpatientswithmetastaticcolorectalcancerexploratoryanalysisofajapanesesocietyforcancerofthecolonandrectummulticenterobservationalstudyregotas AT akitakamakiyama survivalbenefitofcrossoveradministrationofregorafenibandtrifluridinetipiracilhydrochlorideforpatientswithmetastaticcolorectalcancerexploratoryanalysisofajapanesesocietyforcancerofthecolonandrectummulticenterobservationalstudyregotas AT akitakamakiyama survivalbenefitofcrossoveradministrationofregorafenibandtrifluridinetipiracilhydrochlorideforpatientswithmetastaticcolorectalcancerexploratoryanalysisofajapanesesocietyforcancerofthecolonandrectummulticenterobservationalstudyregotas AT tadamichidenda survivalbenefitofcrossoveradministrationofregorafenibandtrifluridinetipiracilhydrochlorideforpatientswithmetastaticcolorectalcancerexploratoryanalysisofajapanesesocietyforcancerofthecolonandrectummulticenterobservationalstudyregotas AT yukimasahatachi survivalbenefitofcrossoveradministrationofregorafenibandtrifluridinetipiracilhydrochlorideforpatientswithmetastaticcolorectalcancerexploratoryanalysisofajapanesesocietyforcancerofthecolonandrectummulticenterobservationalstudyregotas AT takeshisuto survivalbenefitofcrossoveradministrationofregorafenibandtrifluridinetipiracilhydrochlorideforpatientswithmetastaticcolorectalcancerexploratoryanalysisofajapanesesocietyforcancerofthecolonandrectummulticenterobservationalstudyregotas AT naotoshisugimoto survivalbenefitofcrossoveradministrationofregorafenibandtrifluridinetipiracilhydrochlorideforpatientswithmetastaticcolorectalcancerexploratoryanalysisofajapanesesocietyforcancerofthecolonandrectummulticenterobservationalstudyregotas AT masanobuenomoto survivalbenefitofcrossoveradministrationofregorafenibandtrifluridinetipiracilhydrochlorideforpatientswithmetastaticcolorectalcancerexploratoryanalysisofajapanesesocietyforcancerofthecolonandrectummulticenterobservationalstudyregotas AT toshiakiishikawa survivalbenefitofcrossoveradministrationofregorafenibandtrifluridinetipiracilhydrochlorideforpatientswithmetastaticcolorectalcancerexploratoryanalysisofajapanesesocietyforcancerofthecolonandrectummulticenterobservationalstudyregotas AT tomomikashiwada survivalbenefitofcrossoveradministrationofregorafenibandtrifluridinetipiracilhydrochlorideforpatientswithmetastaticcolorectalcancerexploratoryanalysisofajapanesesocietyforcancerofthecolonandrectummulticenterobservationalstudyregotas AT kojiando survivalbenefitofcrossoveradministrationofregorafenibandtrifluridinetipiracilhydrochlorideforpatientswithmetastaticcolorectalcancerexploratoryanalysisofajapanesesocietyforcancerofthecolonandrectummulticenterobservationalstudyregotas AT satoshiyuki survivalbenefitofcrossoveradministrationofregorafenibandtrifluridinetipiracilhydrochlorideforpatientswithmetastaticcolorectalcancerexploratoryanalysisofajapanesesocietyforcancerofthecolonandrectummulticenterobservationalstudyregotas AT yoshihirookita survivalbenefitofcrossoveradministrationofregorafenibandtrifluridinetipiracilhydrochlorideforpatientswithmetastaticcolorectalcancerexploratoryanalysisofajapanesesocietyforcancerofthecolonandrectummulticenterobservationalstudyregotas AT hitoshikusaba survivalbenefitofcrossoveradministrationofregorafenibandtrifluridinetipiracilhydrochlorideforpatientswithmetastaticcolorectalcancerexploratoryanalysisofajapanesesocietyforcancerofthecolonandrectummulticenterobservationalstudyregotas AT daisukesakai survivalbenefitofcrossoveradministrationofregorafenibandtrifluridinetipiracilhydrochlorideforpatientswithmetastaticcolorectalcancerexploratoryanalysisofajapanesesocietyforcancerofthecolonandrectummulticenterobservationalstudyregotas AT koichiokamoto survivalbenefitofcrossoveradministrationofregorafenibandtrifluridinetipiracilhydrochlorideforpatientswithmetastaticcolorectalcancerexploratoryanalysisofajapanesesocietyforcancerofthecolonandrectummulticenterobservationalstudyregotas AT takaotamura survivalbenefitofcrossoveradministrationofregorafenibandtrifluridinetipiracilhydrochlorideforpatientswithmetastaticcolorectalcancerexploratoryanalysisofajapanesesocietyforcancerofthecolonandrectummulticenterobservationalstudyregotas AT kimihiroyamashita survivalbenefitofcrossoveradministrationofregorafenibandtrifluridinetipiracilhydrochlorideforpatientswithmetastaticcolorectalcancerexploratoryanalysisofajapanesesocietyforcancerofthecolonandrectummulticenterobservationalstudyregotas AT masahikogosho survivalbenefitofcrossoveradministrationofregorafenibandtrifluridinetipiracilhydrochlorideforpatientswithmetastaticcolorectalcancerexploratoryanalysisofajapanesesocietyforcancerofthecolonandrectummulticenterobservationalstudyregotas AT yasuhiroshimada survivalbenefitofcrossoveradministrationofregorafenibandtrifluridinetipiracilhydrochlorideforpatientswithmetastaticcolorectalcancerexploratoryanalysisofajapanesesocietyforcancerofthecolonandrectummulticenterobservationalstudyregotas |